| About the Fund DRI Capital manages a fund that acquires royalties from pharmaceutical and biotechnology companies in addition to research institutes, universities and inventors. Acquisition criteria are not limited to any specific therapeutic category and there is a preference for products that have been approved by the FDA and/or the EMEA. Because the investments are long-term in nature the strength of the underlying intellectual property is critical. The DRI Capital team of investment professionals has extensive asset valuation skills, industry assessment expertise and global financial market knowledge to offer industry-leading deal execution. It is our understanding that sellers of royalty interests have used the proceeds from acquisitions to: Pharmaceutical and Biotechnology Companies • Fund clinical and pipeline development • Fund product acquisition, in-licensing and up-front payments • Fund product launches, sales force expansions and commercialization • Reduce concentration risk • Monetize non-core assets and leverage lower ROIs for higher return on investment projects Institutions • Fund research and development initiatives and technology transfer • Reduce concentration risk through diversification • Manage operating budgets • Fund capital campaigns Inventors • Fund philanthropy • Reduce risk • Retirement plan • Tax plan |
©Copyright 2010 DRI Capital Inc.